Your browser doesn't support javascript.
loading
Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance.
Alame-Emane, A K; Xu, P; Pierre-Audigier, C; Cadet-Daniel, V; Shen, X; Sraouia, M; Siawaya, J F Djoba; Takiff, H; Gao, Q; Gicquel, B.
Afiliação
  • Alame-Emane AK; Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France; Research and Specialised Diagnostics Unit, National Laboratory of Public Health, Libreville, Gabon.
  • Xu P; Key Laboratory of Medical Molecular Virology, Institutes of Biomedical Sciences and Institute of Medical Microbiology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Pierre-Audigier C; Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France; Laboratoire de Bactériologie, Bichat-Claude Bernard Hospital, Paris, France.
  • Cadet-Daniel V; Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France.
  • Shen X; Department of Tuberculosis Control, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Sraouia M; Laboratoire de Bactériologie, Bichat-Claude Bernard Hospital, Paris, France.
  • Siawaya JF; Research and Specialised Diagnostics Unit, National Laboratory of Public Health, Libreville, Gabon.
  • Takiff H; Laboratorio de Genética Molecular, Centro de Microbiologia y Biologia Celular, Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela.
  • Gao Q; Key Laboratory of Medical Molecular Virology, Institutes of Biomedical Sciences and Institute of Medical Microbiology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Gicquel B; Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France; Emerging Bacterial Pathogens Laboratory, Institut Pasteur of Shanghai, Shanghai, China.
Int J Tuberc Lung Dis ; 19(6): 679-84, 2015 Jun.
Article em En | MEDLINE | ID: mdl-25946359
ABSTRACT

BACKGROUND:

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (TB) constitute a major public health concern.

OBJECTIVE:

To determine the timing of pncA mutations that confer pyrazinamide (PZA) resistance in relation to mutations conferring resistance to isoniazid (INH) and rifampicin (RMP).

DESIGN:

Isolates from two major urban centres--Paris (101 strains) and Shanghai (171 strains)--were investigated for the association of pncA mutations with resistance to drugs other than PZA.

RESULTS:

The proportion of pncA mutations found in INH-monoresistant strains was not increased.

CONCLUSION:

pncA mutations associated with PZA resistance were found almost exclusively in MDR-TB strains, underlining the importance of determining PZA resistance when treating MDR- or XDR-TB.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Pirazinamida / Rifampina / Tuberculose Resistente a Múltiplos Medicamentos / Fluoroquinolonas / Farmacorresistência Bacteriana Múltipla / Mycobacterium tuberculosis / Antituberculosos Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Humans País/Região como assunto: Asia / Europa Idioma: En Revista: Int J Tuberc Lung Dis Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Pirazinamida / Rifampina / Tuberculose Resistente a Múltiplos Medicamentos / Fluoroquinolonas / Farmacorresistência Bacteriana Múltipla / Mycobacterium tuberculosis / Antituberculosos Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Humans País/Região como assunto: Asia / Europa Idioma: En Revista: Int J Tuberc Lung Dis Ano de publicação: 2015 Tipo de documento: Article